ClinicalTrials.gg
CompletedNCT02577107RELIANCEUpdated Nov 30, 2017Results posted

Head to Head Study of Anti-VEGF Treatment.

A Phase 4 interventional study of ranibizumab and Conbercept in Age-related Macular Degeneration, sponsored by Novartis Pharmaceuticals. Completed at 1 site in China. Per ClinicalTrials.gov, last updated 2017-11-30.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
12
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 125 studies testing ranibizumab in Macular Degeneration — 3 open to participants now, 6 under way, 4 of them phase 3. Ranibizumab · Macular Degeneration.

Enrollment
113th of 124
12 · median 64
Started
2016
with 2 others
Phase 4
33 of 125
none open now
Registered
102nd of 125
by date
Lead sponsor
15 of 125
Novartis Pharmaceuticals

Among the 125 studies testing ranibizumab in Macular Degeneration, this one is the 113th largest by enrollment of the 124 interventional ones that give a count, is one of 3 that started in 2016, is one of 33 in phase 4, and was the 102nd registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

3 of the 125 studies testing ranibizumab in Macular Degeneration are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing ranibizumab in Macular Degeneration, or all of them as a file.
02

Study summary

An exploratory single site, open label, randomized, controlled study evaluated plasma vascular endothelial growth factor levels after intravitreal injection of ranibizumab (Lucentis) and conbercept (Langmu) for neovascular age-related macular degeneration

Read the detailed description

This prospective, randomized, open label study enrolled patients with neovascular AMD who were naïve to anti-VEGF therapy or have not received intravitreal anti-VEGF therapy for the previous 3 months. Patients were randomized in two treatment arms for 3 months:

  • Study arm 1: Three monthly injections of 0.5mg Ranibizumab
  • Study arm 2: Three monthly injections of 0.5mg Conbercept Blood sample (plasma/serum) was collected at baseline (pre-dose), 3h post-injections and days 1, 3, 7 and 28, following doses 1 and 3 for PK and systemic VEGF analysis. The lab staff was blinded for treatment allocation.

Plasma VEGF concentration was measured by a blinded laboratory using Quantikine® ELISA kits. Serum ranibizumab and conbercept concentration will be determined using validated ELISA assay.

The study was divided into 2 stages: the 1st initial feasibility stage with 6 patients per arm (12 patients in total) to verify SD for sample size justification and 2nd stage to confirm the findings with justified sample size.

03

Conditions studied

  • Age-related Macular Degeneration

Keywords

  • Age-related macular degeneration,
  • ranibizumab,
  • conbercept,
  • plasma VEGF
  • PK
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written must be obtained before any assessment is performed.
  2. Male or female patient ≥ 50 years of age.
  3. Subfoveal CNV secondary to nAMD.
  4. BCVA score must be between 73 and 24 letters as measured by ETDRS chart

Exclusion criteria

Exclusion Criteria:

For both eyes

  1. Any active periocular or ocular infection or inflammation
  2. Uncontrolled glaucoma
  3. Neovascularization of the iris or neovascular glaucoma. For study eye
  4. Choroidal neovascularization of any other cause than wet AMD
  5. Ocular disorders present that may confound interpretation of study results,
  6. Previous treatment with verteporfin PDT (Visudyne®), external-beam radiation therapy, focal laser photocoagulation, vitrectomy, submacular surgery, or transpupillary thermotherapy.
  7. Structural damage within 0.5 disc diameter of the center of the macula
  8. Atrophy or fibrosis involving the center of the fovea.
  9. Inability of obtaining required lab report. Ocular medical history
  10. History of intravitreal injection with any anti-VEGF drugs within 3 months. Exclusion criteria for systemic medical conditions and treatment
  11. Any type of systemic disease or its treatment
  12. Any patients diagnosed with tumor.
  13. Stroke or myocardial infarction less than 3 months.
  14. Known to indocyanine green, fluorescein, or any component of the drug formulation.
  15. Use of any systemic anti-VEGF drugs within 6 months. Exclusion criteria for patient
  16. Patients who have participated in other investigational drug study within 60 days.
  17. Pregnant or nursing (lactating) women.
  18. Inability to comply with study or follow-up procedures.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Ranibizumab 0.5 mg

    Three monthly injections of 0.5mg Ranibizumab

    Drug: ranibizumab

  • Active comparator
    Conbercept 0.5 mg

    Three monthly injections of 0.5mg Conbercept

    Drug: Conbercept

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Plasma Vascular Endothelial Growth Factor (VEGF) Concentration After First Injection at Visit 5 (Day 8 +/- 1 Day)

    Change from baseline in plasma Vascular endothelial growth factor (VEGF) concentration after first injection at Visit 5 (Day 8 +/- 1 day).Blood sample was collected for systemic VEGF. VEGF was measured by a blinded laboratory using ELISA kits.

    Time frame: Baseline, Visit 5 (Day 8 +/- 1 day)

Secondary outcomes

  1. Change From Baseline in Plasma Vascular Endothelial Growth Factor (VEGF) Concentration After Third Injection at Visit 10 (Day 67 +/- 1 Day)

    Change from baseline in plasma Vascular endothelial growth factor (VEGF) concentration after third injection at Visit 10 (Day 67 +/- 1 day). Blood sample was collected for systemic VEGF. VEGF will be measured by a blinded laboratory using ELISA kits.

    Time frame: Baseline, Visit 10 (Day 67 +/- 1 day)

  2. Plasma VEGF Concentration at Baseline, Visit 2, 3, 4, 5, 6 After 1st Injection

    Blood sample will be collected for systemic VEGF. VEGF will be measured by a blinded laboratory using ELISA kits. Baseline, Visit Visit 2, 3, 4, 5, 6 after 1st injection

    Time frame: Baseline, Visit 2, 3, 4, 5, 6

  3. Plasma VEGF Concentration at Baseline, Visit 7, 8, 9, 10, 11 After 3rd Injection

    Blood sample will be collected for systemic VEGF. VEGF will be measured by a blinded laboratory using ELISA kits. Baseline, Visit 7, 8, 9, 10, 11 after 3rd injection

    Time frame: Baseline, Visit 7, 8, 9, 10, 11

07

Results

Posted Nov 30, 2017

Participant flow

Participant flow — Overall Study
MilestoneRanibizumab 0.5 mgConbercept 0.5 mg
Started66
Completed65
Not completed01
Withdrew: Protocol deviation01

Outcome measures

PrimaryChange From Baseline in Plasma Vascular Endothelial Growth Factor (VEGF) Concentration After First Injection at Visit 5 (Day 8 +/- 1 Day)

Change from baseline in plasma Vascular endothelial growth factor (VEGF) concentration after first injection at Visit 5 (Day 8 +/- 1 day).Blood sample was collected for systemic VEGF. VEGF was measured by a blinded laboratory using ELISA kits.

Time frame:
Baseline, Visit 5 (Day 8 +/- 1 day)
Reported as:
Mean · pg/mL
Change From Baseline in Plasma Vascular Endothelial Growth Factor (VEGF) Concentration After First Injection at Visit 5 (Day 8 +/- 1 Day)
pg/mLRanibizumab 0.5 mgConbercept 0.5 mg
Change From Baseline in Plasma Vascular Endothelial Growth Factor (VEGF) Concentration After First Injection at Visit 5 (Day 8 +/- 1 Day)5.720 ± 9.5547-25.833 ± 22.8145
Statistical analysis
  • Ranibizumab 0.5 mg vs Conbercept 0.5 mg · Mean difference (final values): 20.314 · 95% CI 9.618 to 31.011
SecondaryChange From Baseline in Plasma Vascular Endothelial Growth Factor (VEGF) Concentration After Third Injection at Visit 10 (Day 67 +/- 1 Day)

Change from baseline in plasma Vascular endothelial growth factor (VEGF) concentration after third injection at Visit 10 (Day 67 +/- 1 day). Blood sample was collected for systemic VEGF. VEGF will be measured by a blinded laboratory using ELISA kits.

Time frame:
Baseline, Visit 10 (Day 67 +/- 1 day)
Reported as:
Mean · pg/mL
Change From Baseline in Plasma Vascular Endothelial Growth Factor (VEGF) Concentration After Third Injection at Visit 10 (Day 67 +/- 1 Day)
pg/mLRanibizumab 0.5 mgConbercept 0.5 mg
Change From Baseline in Plasma Vascular Endothelial Growth Factor (VEGF) Concentration After Third Injection at Visit 10 (Day 67 +/- 1 Day)-0.100 ± 17.4799-22.220 ± 12.9239
SecondaryPlasma VEGF Concentration at Baseline, Visit 2, 3, 4, 5, 6 After 1st Injection

Blood sample will be collected for systemic VEGF. VEGF will be measured by a blinded laboratory using ELISA kits. Baseline, Visit Visit 2, 3, 4, 5, 6 after 1st injection

Time frame:
Baseline, Visit 2, 3, 4, 5, 6
Reported as:
Mean · pg/mL
Plasma VEGF Concentration at Baseline, Visit 2, 3, 4, 5, 6 After 1st Injection
pg/mLRanibizumab 0.5 mgConbercept 0.5 mg
Baseline31.400 ± 6.381642.200 ± 23.4269
Visit 2 (Day 1)30.958 ± 19.981314.920 ± 12.4920
Visit 3 (Day 2 +/- 1)36.517 ± 19.278324.590 ± 39.2435
Visit 4 (Day 4 +/- 1)29.150 ± 5.55877.213 ± 4.9250
Visit 5 (Day 8 +/- 1)37.000 ± 4.797919.075 ± 4.5051
Visit 6 (Day 30 +/- 4)27.092 ± 13.235625.270 ± 15.0967
SecondaryPlasma VEGF Concentration at Baseline, Visit 7, 8, 9, 10, 11 After 3rd Injection

Blood sample will be collected for systemic VEGF. VEGF will be measured by a blinded laboratory using ELISA kits. Baseline, Visit 7, 8, 9, 10, 11 after 3rd injection

Time frame:
Baseline, Visit 7, 8, 9, 10, 11
Reported as:
Mean · pg/mL
Plasma VEGF Concentration at Baseline, Visit 7, 8, 9, 10, 11 After 3rd Injection
pg/mLRanibizumab 0.5 mgConbercept 0.5 mg
Baseline36.250 ± 11.861036.520 ± 19.2278
Visit 7 (Day 60 +/- 4)34.383 ± 12.77275.720 ± 2.1690
Visit 8 (Day 61 +/- 1)46.533 ± 48.12936.820 ± 4.6287
Visit 9 (Day 63 +/- 1)54.067 ± 40.25858.070 ± 4.6452
Visit 10 (Day 67 +/- 1)36.150 ± 25.439914.300 ± 9.6690
Visit 11 (Day 90 +/- 4)45.067 ± 18.082856.020 ± 27.0819

Adverse events

Collected over Adverse events are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All adverse events reported in this record are from date of First Patient First Treatment until Last Patient Last Visit.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ranibizumab 0.5 mg—0/6 (0%)1/6 (16.7%)
Conbercept 0.5 mg—2/6 (33.3%)3/6 (50%)
Most frequent serious events
Most frequent serious events
EventRanibizumab 0.5 mgConbercept 0.5 mg
Infectious pneumoniaInfections and infestations0/61/6
Craniocerebral injuryInjury, poisoning and procedural complications0/61/6
Fracture of jawInjury, poisoning and procedural complications0/61/6
Fracture of ribInjury, poisoning and procedural complications0/61/6
Pulmonary contusionInjury, poisoning and procedural complications0/61/6
Thoracic injuryInjury, poisoning and procedural complications0/61/6
COPDRespiratory, thoracic and mediastinal disorders0/61/6
Most frequent other events
Most frequent other events
EventRanibizumab 0.5 mgConbercept 0.5 mg
DizzinessEar and labyrinth disorders0/61/6
Conjunctival congestionEye disorders0/61/6
Upper respiratory infectionInfections and infestations1/61/6
HeadacheNervous system disorders0/61/6
MigraineNervous system disorders1/60/6
CoughRespiratory, thoracic and mediastinal disorders0/61/6

Baseline characteristics

Age, Continuous
Age, Continuous(years)Ranibizumab 0.5 mgConbercept 0.5 mgTotal
Mean65.3 ± 5.5069.3 ± 8.4167.3 ± 7.09
Sex: Female, Male
Sex: Female, Male(Participants)Ranibizumab 0.5 mgConbercept 0.5 mgTotal
Female011
Male6511
08

Study locations

1 site
  • Novartis Investigative Site
    Chengdu, Sichuan 610041, China
09

References and documents

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2016 to primary completion in Jul 2016, 5 months.

Results were first posted in Nov 2017, 1 year 4 months after primary completion.

Of 24 industry-sponsored phase 4 interventional studies under Macular Degeneration, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 36. This study's 5 months is below that.

Counting every sponsor, half of 45 studies reached it within 26 months; a quarter within 14 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2015
First posted
Oct 16, 2015
StartActual
Jan 13, 2016
Primary completionActual
Jul 9, 2016
CompletionActual
Jul 9, 2016
Results first posted
Nov 30, 2017
Last update
Nov 30, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 30, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02577107
Responsible party
Sponsor
First posted
Oct 16, 2015
Start date
Jan 13, 2016
Primary completion
Jul 9, 2016
Completion
Jul 9, 2016
Results posted
Nov 30, 2017
Last update
Nov 30, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion